

# Infiltrating T cells promote renal cell carcinoma (RCC) progression *via* altering the estrogen receptor $\beta$ -DAB2IP signals

Chiuan-Ren Yeh<sup>1,2</sup>, Zheng-Yu Ou<sup>1</sup>, Guang-Qian Xiao<sup>2</sup>, Elizabeth Guancial<sup>3</sup>, Shuyuan Yeh<sup>1,2</sup>

<sup>1</sup>Department of Urology, University of Rochester Medical Center, Rochester, NY 14642, USA

<sup>2</sup>Department of Pathology, University of Rochester Medical Center, Rochester, NY 14642, USA

<sup>3</sup>Department of Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA

## Correspondence to:

Shuyuan Yeh, e-mail: shuyuan\_yeh@urmc.rochester.edu

**Keywords:** ER $\beta$ , RCC, metastasis, DAB2IP, CD4+ T cells

**Received:** August 12, 2015

**Accepted:** October 13, 2015

**Published:** November 17, 2015

## ABSTRACT

Previous studies indicated the T cells, one of the most common types of immune cells existing in the microenvironment of renal cell carcinoma (RCC), may influence the progression of RCC. The potential linkage of T cells and the estrogen receptor beta (ER $\beta$ ), a key player to impact RCC progression, however, remains unclear. Our results demonstrate that RCC cells can recruit more T cells than non-malignant kidney cells. Using an *in vitro* matrigel invasion system, we found infiltrating T cells could promote RCC cells invasion *via* increasing ER $\beta$  expression and transcriptional activity. Mechanism dissection suggested that co-culturing T cells with RCC cells released more T cell attraction factors, including IFN- $\gamma$ , CCL3 and CCL5, suggesting a positive regulatory feed-back mechanism. Meanwhile, infiltrating T cells may also promote RCC cell invasion *via* increased ER $\beta$  and decreased DAB2IP expressions, and knocking down DAB2IP can then reverse the T cells-promoted RCC cell invasion. Together, our results suggest that infiltrating T cells may promote RCC cell invasion *via* increasing the RCC cell ER $\beta$  expression to inhibit the tumor suppressor DAB2IP signals. Further mechanism dissection showed that co-culturing T cells with RCC cells could produce more IGF-1 and FGF-7, which may enhance the ER $\beta$  transcriptional activity. The newly identified relationship between infiltrating T cells/ER $\beta$ /DAB2IP signals may provide a novel therapeutic target in the development of agents against RCC.

## INTRODUCTION

Renal cell carcinoma (RCC) is the most common kidney cancer and third leading cause of death among urological tumors [1]. There are four subtypes of RCC and clear cell tumor subtype is the most common type, accounting for 80% of all RCCs [2]. The inactivating mutation in the von Hippel-Lindau (VHL) gene, a tumor suppressor, is frequently observed in clear cell RCC [3]. RCC patients can easily develop resistance to chemotherapy and radiation therapy, therefore kidney resection is considered to be the effective treatment for patients with clinically localized RCC. Unfortunately, the postoperative recurrence in RCC patients who undergo curative nephrectomy is only around 20% to 40% and

rarely curable [4]. Thus, there is a clear need to improve treatment options for metastatic RCC.

The tumor microenvironment (TME) with infiltrated immune cells may play key roles in tumor progression [5]. RCC has been well recognized as an immune escape disease. This could be due to alterations in the tumor itself resulting in its impaired recognition by the immune system or by the dysfunction of immune cells in RCC patients [6]. Furthermore, immune dysfunction contributing to tumor invasion has been reported in some RCC patients [7]. The most common types of immune cells in RCC tumors are T cells and natural killer cells [8]. Regulatory T cells (Treg), a subpopulation of CD4+ T cells, have been demonstrated to suppress the self-reactive T cells [9, 10]. Furthermore, it is reported that Treg cells have a modest

enrichment among these tumor recruited T lymphocytes [11]. Importantly, the increased Treg cells population is found to be associated with a poor prognosis in women with advanced ovarian cancer and was implicated in preventing the induction of effective antitumor immunity [12]. In the present report, we study the novel mechanisms by which how T cells regulate RCC invasion.

The effects of estrogens are evident through their binding to estrogen receptors (ERs) and subsequent regulation of the transcription and activation of downstream genes. There are two subtypes of ERs, ER alpha and beta (ER $\alpha$  and ER $\beta$ ). The distribution of ER $\alpha$  and ER $\beta$  varies in different tissue types and affect tumor progression, including breast, prostate and bladder cancers [13–19]. It was reported that there is only ER $\beta$ , but no ER $\alpha$ , expression in cultures of RCC cells and in human RCC tissues [20]. The ER $\beta$  roles in RCC progression, however, remain to be further studied. In this study, we investigate the role of recruited T cells in RCC and their potential linkage to ER $\beta$  expression in promoting the RCC cell invasion.

## RESULTS

### RCC cells can better attract CD4<sup>+</sup> T cells than the non-malignant kidney cells


To examine the potential impacts of CD4<sup>+</sup> T cells in the RCC development, we first tested whether RCC cells, compared to non-malignant kidney cells, could better attract the CD4<sup>+</sup> T cells, HH, which were used in this study. We applied the *in vitro* transwell migration assay to study the effects of RCC cells on T cell recruitment. The T cells were then seeded in the upper transwells (pore size, 5  $\mu$ m) and

2 different RCC cells 786-O and A498, or nonmalignant kidney HKC-2 cells were seeded in the bottom wells. After 6 hours of incubation, T cells that were attracted by RCC or non-malignant kidney cells and migrated into the bottom well were counted. The result (Fig. 1) revealed that RCC 786-O cells could recruit more T cells ( $2.1 \pm 0.23$  fold) than HKC-2. Compared to HKC-2 cells, A498 cells could better attract the T cells ( $\sim 1.7 \pm 0.1$  fold) (Fig. 1). All results have been repeated independently 3 times. Together, our data suggested that RCC cells could better attract CD4<sup>+</sup> T cells than the non-malignant kidney cells.


### Recruited T cells enhanced the RCC cell invasion via up-regulation of ER $\beta$ signaling in RCC cells

To further study the consequences of recruited CD4<sup>+</sup> T cells on RCC progression, we then applied the matrigel transwell invasion assay to test the invasion capability of RCC cells co-cultured with or without differentiated T cells for 2 days. The cells were then re-seeded in the upper transwell ( $5 \times 10^4$ /well). The invasion results showed that an increased invasion ability in RCC cells that have been co-cultured with T cells as compared with RCC without co-culture (Fig. 2). Co-culturing with T cells can increase 786-O cell invasion capability to  $2.5 \pm 0.75$  fold and A498 cells to  $3.7 \pm 1.2$  fold.

To dissect the potential mechanisms why recruited T cells can enhance RCC cell invasion, we examined several potential factors that could influence the RCC invasion. Those signal pathways include ER $\beta$ , VEGFA and HIF2 $\alpha$  [20–22]. After characterization, we identified ER $\beta$  can be specifically up-regulated and the disabled homolog 2-interacting protein (DAB2IP) can be specifically



**Figure 1: RCC cells can better attract CD4<sup>+</sup> T cells than the non-malignant kidney cells.** Transwell migration assay was applied to study the capability of RCC cell to attract T cells. Non-malignant kidney cells (HKC2) and RCC cells (786-O and A498) were seeded in the lower chamber of transwells, and T cells were placed in the upper chambers with 5  $\mu$ m pore size members. After 6 hrs of incubation, the media in the bottom well was collected and numbers of migrated T cells were counted by BioRed T20 cell counting system. Each experiment was independently repeated three times, each time in triplicate. \* $p < 0.05$  vs HKC-2.



**Figure 2: Recruited T cells could promote RCC cells invasion.** RCC cells, 786-O and A498, were cultured alone or co-cultured with T cells for 48 hrs. In a transwell system, the RCC cells with/without being co-cultured were re-seeded into the inserted wells that were pre-coated with matrigel for invasion assay. Invaded cells were stained by 1% toluidine blue (upper panels) and quantifications of invaded cells are presented in bottom panel. Each experiment was independently repeated three times, each time in triplicate. \* $p < 0.05$  vs RCC alone.


down-regulated in RCC cells after co-culture with T cells (refer to Fig. 4A). The pathways are specific as VEGFa and HIF2 $\alpha$  did not change in RCC cells after co-culturing with T cells for 48 hrs (refer to Fig. 4A).

Among those changed factors, we focused on studying ER $\beta$  as recent reports indicated that ER $\beta$  could play important roles to influence the RCC cell invasion [20]. We first assayed the ER $\beta$  transactivation activity, Fig. 3A results revealed that E2 treatment, as a positive control, could activate ER $\beta$  transactivation in 293T cells by (ERE)<sub>3</sub>-Luciferase reporter assay. Furthermore, conditional conditioned media (CM) from co-cultured 786-O cells and T cells could better induce the (ERE)<sub>3</sub>-luciferase- activity by ~2.9 fold compared to control media. The induction effect of CM from co-culture is also better than CM collected from 786-O cells only or T cells only (Fig. 3A)


In addition to observing that co-culture CM could stimulate the transactivation of ER $\beta$ , results from western

blot analysis indicated that co-culturing RCC cells and T cells could increase ER $\beta$  protein expression in 786-O and A498 cells (Fig. 3B), suggesting that recruited T cells may promote RCC cell invasion *via* increasing the activity and expression level of ER $\beta$ . Importantly, using the interruption approach, with ER $\beta$ -shRNA to knock down ER $\beta$  mRNA, results revealed that knockdown of ER $\beta$  could block/reverse the recruited T cells-enhanced RCC cell invasion in both 786-O and A-498 cells (Fig. 3C). Similar results were also obtained when we replaced ER $\beta$ -shRNA with the anti-estrogen ICI182,780 showing the inhibition of ER $\beta$  activity by anti-estrogen could reverse recruited T cells-enhanced RCC cell invasion in 786-O (Fig. 3D).

Together, results from Fig. 3A–3D suggest that recruited T cells can enhance RCC cell invasion at least partly *via* increasing the ER $\beta$  expression and transactivation.



**Figure 3: Co-culture of RCC and CD4+ T cells (HH) can activate ERβ transcriptional activity and increase ERβ expression in RCC cells.** **A.** ERβ transcriptional activity was increased by the conditioned media (CM) collected from co-cultured cells. 293T cells were transfected with ERβ, and (ERE)<sub>3</sub>-luciferase reporter plasmid by lipofectamine 3000 following the manufacturer's protocol. CM was collected from RCC alone, T cells alone, or RCC+T cells co-culture and was used to treat 293T cells after 48 hrs transfection with ERβ and (ERE)<sub>3</sub>-luciferase reporter or control plasmids. 10 nM E2 treatment was applied as positive control for induction of ERβ activity. \**p* < 0.05 vs vector. **B.** Co-culture with T cells could increase ERβ protein expression in RCC cells. ERβ protein was detected by anti-ERβ polyclonal antibody (GTX 110607, GeneTex) at 1 to 1000 dilution in 1 × PBS with 5% BSA. \*, #, § *p* < 0.05; \* vs shLuc without T cell co-culture; # vs shLuc with T cells; § vs shERβ without T cell co-culture. **C.** T cells co-culture-induced ERβ can enhance RCC cell invasion. We introduced shERβ or shLuc in RCC cells, and then RCC cells were co-cultured with T cells. After incubating 48 hrs, RCC cells were re-seeded into upper wells of a transwell system to perform the matrigel invasion assay. \* vs shLuc without T cell co-culture; # vs shLuc with T cell co-culture; \*, # *p* < 0.05. **D.** Increased ERβ plays important roles in the T cells-enhanced RCC invasion. ER antagonist, ICI182,780 (1 μM), or mock control was used to treat 786-O cells for 24 hrs. Those 786-O cells were either cultured alone, or co-cultured with T cells for 48 hrs. RCC Cells were then seeded in the matrigel pre-coated insert wells for the transwell invasion assay. Each experiment was independently repeated three times, each time in triplicate. \*, #, § *p* < 0.05 \* vs 786-O no treatment; # vs 786-O+T cell no treatment T cell; § vs 786-O with ICI treatment



**Figure 4: Recruited T cells can promote RCC cell invasion through ERβ/DAB2IP signal pathway.** A–B. Co-culture of RCC cells with T cells can increase ERβ, but decrease DAB2IP expression, in both 786-O and A498 cells. Total cell lysates were collected from RCC cells cultured alone or co-cultured with T cells for 48 hr. 50 μg of total protein was loaded in each well, anti-ERβ and anti-DAB2IP antibodies were used to detect their protein levels. \* $p < 0.05$ . C. ERβ could inhibit DAB2IP protein expression level in RCC. Total cell lysates were collected from RCC cells cultured alone or with T cells. DAB2IP expression was compared between these two conditions (left panels). ERβ could inhibit DAB2IP expression (right panels). DAB2IP protein level was compared between 786-O/sh control (shLuc) and 786-O/shERβ. D. ERβ-induced RCC invasion may function through down-regulation of DAB2IP. Lentiviral shERβ or shLuciferase (shLuc) was used to study the ERβ knockdown effects on RCC cell invasion. Our data showed that shERβ could reduce the RCC cell invasion. As ERβ knockdown can lead to the increased DAB2IP, we next tested whether knockdown of DAP2IP could reverse the ERβ knockdown-reduced RCC invasion. Lentiviral shDAB2IP or scramble control (shcon) were transduced into 786-O cells. 786-O cells express a high endogenous ERβ, thus 786-O cells are used to knock down ERβ for functional assay. After lentiviral transduction of different shRNA and controls, puromycin selection was used to enrich the transduced 786-O cells. Cells were then co-cultured with/without T cells, and then re-seeded to a new transwell matrigel invasion system to study the roles of ERβ and DAB2IP in 786-O cells invasion. The invaded 786-O cells were stained with 1% toluidine B in PBS (bottom panel). Quantifications of invaded 786-O cells were shown in right panel. \*, #, § and \$  $p < 0.05$  \* vs shLuc/sh con 786-O; # shERβ/shcon in 786-O; § vs shLuc/shcon in 786-O+T cells; \$ vs shERβ/shcon in 786-O+T cells.

## Mechanisms study by which T cells can enhance ER $\beta$ expression and lead to the increased RCC cell invasion

To further dissect the molecular mechanism(s) that are responsible for T cells-enhanced ER $\beta$  expression and increased RCC cell invasion, we applied Q-PCR-based focus-array to quantify the expressions of several key metastasis-related genes. Among those altered metastasis-related genes, we found the expression of DAB2IP was decreased when ER $\beta$  expression was increased in RCC 786-O and A498 cells (Fig. 4A and 4B). DAB2IP has been reported to function as a suppressor for cancer progression [23–25]. Consistent with mRNA level changes, using Western Blot analyses we also found co-culturing RCC cells with T cells could up-regulate ER $\beta$  in RCC cells (see Fig. 3B) and down-regulate DAB2IP (Fig. 4C, left panels). Importantly, we observed that knockdown of ER $\beta$  by shRNA up-regulated DAB2IP expression in RCC 786-O cells (Fig. 4C, right panels).

To further investigate the functions and the correlation of DAB2IP in ER $\beta$ -promoted RCC invasion, we knocked down DAB2IP in 786-O cells that have been transduced with lentiviral shER $\beta$  and the results showed that knockdown of DAB2IP can reverse shER $\beta$ -reduced 786-O invasion (Fig. 4D).

Data presented in Fig. 4 suggested that co-culturing T cells with RCC cells could increase ER $\beta$  signals in RCC and the increased ER $\beta$  negatively regulates the expression of tumor suppressor DAB2IP. Together, the recruited T cells can enhance RCC cell invasion *via* altering the ER $\beta$   $\rightarrow$  DAB2IP signals.

## Mechanisms by which tumor cells attract T cells into the RCC tumor microenvironment

We further studied why RCC can recruit T cells into the tumor microenvironment. We hypothesize a positive regulatory feed-back mechanism might exist. We first analyzed T cells recruitment related cytokines [26] in RCC cells after co-culture with T cells. The results indicated IFN- $\gamma$ , CCL3 and CCL5 were increased in both RCC cells after co-culture (Fig. 5A). Interestingly and importantly, the expressions of IFN- $\gamma$ , CCL3 and CCL5 were also increased in T cells after co-cultured with 786-O or A498 RCC cell lines (Fig. 5B). In addition, we found knockdown of ER $\beta$  in 786-O cells, that have been pre-incubated with T cells for 48 hrs, could suppress the infiltrating T cells mediated increase of IFN- $\gamma$ , CCL3 and CCL5 in 786-O cells (Fig. 5C).

Together, these results indicate that the recruited T cells could function *via* increasing IFN- $\gamma$  expression in both RCC and T cells using a positive regulatory feed-back mechanism to enhance T cells migration into the RCC tumor microenvironment. Importantly, the recruited T cells could subsequently increase ER $\beta$  expression in

RCC cells to promote RCC cell invasion, and the increased ER $\beta$  in RCC cells could further increase IFN- $\gamma$  expression in T cells to further promote T cells recruitment, by a positive-feedback mechanism.


In addition to IFN- $\gamma$ , we found that the co-culture of T cells with RCC cells could increase the expression of IGF-1 and FGF7 in T cells (Fig. 5B), and knocking down ER $\beta$  in 786-O cells could reverse the T cells/RCC cells co-culture-enhanced IGF-1 and FGF-7 production from T cells (Fig. 5C). This is important since growth factor signals could activate ERs transcriptional activity [27]. It will be interesting to test if T cells may also function through secretion of IGF-1 and FGF7 to increase RCC ER $\beta$  in a positive feedback mechanism to enhance RCC cell invasion.

Furthermore, we obtained similar results in T cells, knocking down ER $\beta$  in T cells could consequently suppress the co-cultured RCC cells invasion (Fig. 6A), and knocking down ER $\beta$  in T cells could also reverse the T cells/RCC co-culture-enhanced IFN- $\gamma$  and IGF-1 in T cells (Fig. 6B).

## DISCUSSION

RCC is the major type (85–90%) of renal cancer and is categorized as a highly vascularized tumor with high metastatic incidence. Based on the clinical cases analysis, there are 25%–33% of RCC patients who develop metastatic disease, and 20%–40% of patients who undergo treatment for localized disease will eventually develop metastases [28]. More than 50% of patients with early stage RCC are cured by surgery to remove the tumor and the 5-year survival rate is around 74–81%. However, the outcome for that late stage RCC is only around 8%, based on the updated website information of the American Cancer Society. It is important to seek new therapeutic strategies to treat RCC patients. Our study indicates T cells can promote RCC invasion *via* increasing the expression of ER $\beta$  and decreasing DAB2IP in RCC cells.

In addition to tumor cells, the tumor tissues also include immune cells and several types of secretion factors, including growth factors, cytokines, chemokines, and components of the extracellular matrix. The interaction between immune cells and cancer malignant cells is a complicated process and the immune system may either promote or inhibit cancer progression [29]. A recent study indicated that infiltrated immune cells can promote cancer progression and invasion [30]. A growing body of evidence showed that the existence of regulatory T cells (Treg) may induce tumor cells to change cell secretary profiles and to develop abilities to successfully evade the host immune system [31–33]. Meanwhile, the increased numbers of recruited T cells and mast cells in tumor tissues are also correlated with tumor progression and have been demonstrated to be




**Figure 5: RCC cells promote T cells to express more IGF, FGF and IFN- $\gamma$ , which could then activate the ER $\beta$  pathway in RCC cells.** RCC and T cells were co-cultured for 48 hrs, the RCC or T cells were separated, and then metastasis-related gene expressions were analyzed by Q-PCR. **A.** RCC cells (with T cells) vs RCC cells (only). \* $p < 0.05$ . **B.** T cells (with RCC co-culture) vs T cells (only). **C.** ER $\beta$  in RCC could affect T cells activity. RCC cells with/without ER $\beta$  knockdown cultured alone, or co-cultured with T cells. After 48 hrs incubation, target genes were analyzed in T cells. \*, # $p < 0.05$  \* vs T cell alone; # vs T cell+786-O shLuc

prognostic factor(s) in predicting clinical outcomes [34, 35]. In RCC, Polimeno *et al.* indicated that Treg cells CD4+/CD25(high+)/FOXP3+ (forkhead box protein 3) were greater in the patients with RCC ( $p < 0.001$ ) than other types of immune cell cancers. Meanwhile, Kaplan-Meier analysis for disease-free survival showed that high numbers of Treg cells predict short disease-free survival in patients with RCC [36]. This result indicates the important roles of Tregs in the suppression of the anti-tumor immune response. It is well known that CD4+CD25+ and FOXP3 are major markers for Treg cells. Although HH cells have been identified as CD4+ but CD25-, inducible Tregs (iTregs) originate as CD4+ cells from the thymus, and following adequate antigenic stimulation in the presence of cognate antigen and specialized immunoregulatory cytokines, such as TGF- $\beta$ , IL-10, and IL-4; Tregs can be differentiated into CD25+ and FOXP3+ expressing Tregs

hence are called “adaptive” or “inducible” Tregs [37]. The HH cells we used could be transformed to Treg cells and promote RCC progression. Indeed, our unpublished data showed that the CD25 expression was increased in HH cells after co-culture with RCC cells, indicating that the interaction between RCC cells and T cells may facilitate the transformation of HH cells to Treg-like cells.

DAB2IP is a member of the RasGTPase-activating protein family. It interacts directly with DAB2, which suppresses the growth of many cancer types [38, 39]. DAB2IP can suppress the PI3K/Akt pathway and enhance ASK1 activation leading to cell apoptosis. In metastatic prostate cancer (PCa), DAB2IP expression is often down-regulated and results in PI3K/Akt activation and ASK1-JNK inactivation leading to accelerated PCa growth [40]. In addition to its role in PCa, down-regulation of DAB2IP increased cell proliferation and



**Figure 6: Co-culture of RCC cells with T cells can enhance IFN- $\gamma$  and IGF production in T cells via increasing ER $\beta$  in T cells.** T cells transduced with lentiviral ER $\beta$  or shLuc were subjected to puromycin selection to establish the stable clones in T cells. **A.** T cells, with shER $\beta$  or with shLuc, were co-cultured with 786-O cells to test the invasion capability. \*  $P < 0.05$ , \*vs 786-O cells only. **B.** ER $\beta$ , IFN- $\gamma$  and IGF-1 gene expression in T cells (shLuc, shER $\beta$ ) alone and co-cultured with RCC cells. Each experiment was independently repeated 3 times. \*, #  $p < 0.05$ , \*vs T cells shLuc alone; # vs T cell shLuc+786-O;  $p \leq 0.05$  was considered statistically significant.

invasion in bladder cancer [41]. A recent study also showed the loss of DAB2IP gene expression in different subtypes of renal cell carcinoma [42]. Hsieh's study indicated that DAB2IP was detected in 95% (38/40) of normal kidney tissues, but decreased or loss of DAB2IP expression was detected in 56.6% (159/281) of RCC tissues. In knocked down DAB2IP RCC cell lines, HIF- $\alpha$  expression, important in promoting RCC metastasis, was increased. DAB2IP, as a novel tumor suppressor, could prevent RCC metastasis via inhibiting HIF- $\alpha$  [42]. To the best of our knowledge, our study is the first to demonstrate the correlation between ER $\beta$  and DAB2IP. DAB2IP expression was down-regulated when T cells increased the ER $\beta$  expression in RCC cell lines. Our data demonstrate that the increased ER $\beta$  expression could diminished DAB2IP protein levels. However, there was no evidence that ER $\beta$  binds directly to DAB2IP. Previous studies have demonstrated EZH2 can decrease DAB2IP expression [43] and E2 can increase EZH2 through ERs and tumor progression [44]. Together, these results demonstrate E2 may promote cancer progression through the ERs/EZH2/DAB2IP pathway.

Our data showed that IFN- $\gamma$ , CCL3 and CCL5 expression levels increased in both T cells and RCC cells after co-culture. A previous study demonstrated that increasing IFN- $\gamma$  can enhance T cells migration to tumors [45]. Meanwhile, *in vivo* animal studies showed that co-injection of IFN- $\gamma$  with other inflammatory factors can increase T lymphocyte migration via up-regulating the expression of CXCL10 or CCL5 [26]. There are two types of chemokine receptors, CCR5 and CXCR3, involved in T cell recruitment [38, 46–48] and it is well-known that IFN- $\gamma$  can increase CCR5 expression in several types of cells [49], including CD4+ T cells [50]. The CCR5 ligands, including CCL3, CCL4 and CCL5, can conjugate with CCR5 and may enhance the attraction of T cells. CCL3 is also involved in CD4+ T cell recruitment [51] and is very efficient in recruiting T cells [52]. In sarcoidosis patients, sarcoidosis increases the attraction of CD4+ T cells through the release of CCL4, either alone or together with Th1/Tc1-associated cytokines [53]. However, our results showed that co-culturing RCC with T cells only increased CCL3 and CCL5, but not CCL4. Interestingly, although CCL4 expression did not change in RCC cells or T cells after



co-culture, knocking down ER $\beta$  in 786-O cells and then co-culturing with T cells can lead to an increased CCL4 expression in the T cells. It has been known that the miR-125b can down-regulate CCL4 expression in monocytes and T cells by binding of the 3'UTR of CCL4 [54]. Meanwhile, activating transcription factor 3 (ATF3) also was found to repress the expression of CCL4 in murine macrophages [55]. Both studies showed the possible mechanisms involved in the down-regulation of CCL4 in T cells. According to our results, ER $\beta$  in RCC cells may function through paracrine factors to increase miR-125b, and subsequently decrease CCL4 in T cells. Therefore, we could observe the increased CCL4 expression in T cells when ER $\beta$  was knocked down in RCC cells. This may require more detailed experimental study in the future regarding the mechanisms and clinical significance about this ER $\beta$ -regulated CCL4 in the RCC tumor microenvironment.

We also demonstrated the CM from RCC alone can slightly activate ER $\beta$  transcriptional activity and CM from RCC and T cells can further enhance this effect (Fig. 3). After studying the gene profiles, we found IGF expression increased in both RCC and T cells after co-culture and knock down of ER $\beta$  can reverse co-cultured induced IGF expression (Figs. 6 and 7). A previous study indicated that IGF-1 can activate EREs through ERs mediated transcriptional activation in breast cancer [27]. Meanwhile, IGF also can conjugate with IGF-1R (IGF-1 receptor) and insulin receptors to modulate ER $\alpha$  and ER $\beta$  translocation to the nuclei, membrane organelles, and the mitochondria *via* an estrogen independent pathway [56]. These results indicated that recruited T cells have the potential to activate ER $\beta$  in RCC cells and promote RCC progression.

We demonstrated RCC cells have better T cell recruitment ability compared to normal kidney cells and the consequence of T cell recruitment could enhance RCC invasion (Fig. 7). Mechanistic studies showed that after T cells migrated toward RCC cells, both ER $\beta$  transcriptional activity and protein expression increased, but DAB2IP, a tumor suppressor gene, decreased. In addition to ER $\beta$ , IFN- $\gamma$ , CCL3, CCL5 and IGF also increased in both RCC and T cells after co-culture. IFN $\gamma$ , CCL3 and CCL5 may correlate with T cell recruitment and IGF, instead of E2, has been demonstrated able to activate ERs activity. All these increased genes were regulated by ER $\beta$ . The newly identified relationship between T cells and RCC cell ER $\beta$ /DAB2IP pathway may help to establish a new biomarker for predicting the RCC progression, as well as a therapeutic target in the development of agents against RCC.

## MATERIALS AND METHODS

### Cell lines

Two RCC cell lines, 786-O and A498, and CD4+ T cells were purchased from the American Type Culture Collection (ATCC) (Rockville, MD). 786-O and A498

cells were maintained in DMEM media with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. CD4+ T cell was maintained in DMEM with 10% heat inactivated FBS with 1% penicillin/streptomycin. CD4+ T cells were differentiated by treating with 1% dimethylsulfoxide (DMSO) for one week before used in experiments. DMSO or phorbol esters is often used to differentiate immune cells [57, 58].

### Cell migration assay

786-O and A498 and normal human kidney proximal tubular cell line, HKC-2, at  $1 \times 10^5$ , were plated into the lower chambers of the transwells with 5  $\mu$ m pore polycarbonate membrane inserts.  $1 \times 10^5$  differentiated CD4+ T cells (HH) were plated onto the upper chambers. After 6 hrs, the cells migrated into the lower chambers were collected and counted by the Bio-Rad TC10 automatic cell counter. Each data point was performed in triplicate and the experiments were independently repeated twice.

### Invasion assay


The effects of T cells in RCC cell invasion capability was determined using the transwell invasion assay. 786-O and A498 cells were co-cultured with CD4+ T cell for 48 hrs. To set up the cell co-culture, T cells were seeded into the upper chamber (pore size 0.4  $\mu$ m) at  $1.5 \times 10^4$  cells/chamber and co-cultured with RCC cells at  $1.5 \times 10^5$ /well with DMEM including 10% heat inactivated FBS in lower Chamber. After co-cultured for 48 hr, RCC cells were trypsinized and reseeded into transwells that were pre-coated with matrigel (0.2 mg/ml; 100  $\mu$ l/well) for 24 hrs to determine their invasion ability. The invaded RCC cells attached to the lower surface of the membrane were fixed by 75% ethanol and stained with 1% toluidine blue. Cell numbers were counted in five randomly chosen microscopic fields per membrane.

### Estrogen response element luciferase promoter assay

(ERE)<sub>3</sub> luciferase activity was performed using Lipofectamine 3000 (Invitrogen). 293T cells were transfected with 0.1  $\mu$ g pcDNA ER $\beta$ , 0.4  $\mu$ g (ERE)<sub>3</sub>-Luc and 1 ng pRL-TK-Luc reporter gene. After transfection, the media were refreshed to 10% charcoal/dextran stripped-FBS media for 24 hrs and CM collected from RCC and T cells co-cultured system was added as indicated for another 24 hrs. Cells were then harvested for the dual luciferase assay (Promega, Madison, WI).

### Plasmids and ientivirus infection

To overexpress ER $\beta$ , cDNA of ER $\beta$  was cloned into pWPI vector and to silence ER $\beta$  expression, the



**Figure 7: Schematic presentation of the interaction mechanisms of T cells with RCC cells in the tumor microenvironment.** After T cells migrated toward RCC cells, both ER $\beta$  transcriptional activity and protein expression increase, but DAB2IP expression decreases in RCC cells. In addition to ER $\beta$ , IFN- $\gamma$ , CCL3, CCL5, IGF and FGF7 also increased in both RCC and T cells after co-culture. IFN- $\gamma$  and CCL3 and CCL5 may correlate with T cell recruitment. In addition to E2, IGF and FGF7 have been demonstrated to activate ERs transactivation. All these increased genes were regulated by ER $\beta$  when the infiltrated T cells interact with RCC cells in the tumor microenvironment.

shER $\beta$  sequence was cloned into PLKO.1 backbone. The 293T packaging cells were transiently transfected with pMD2.G and psPAX2 with PLKO.1-shluc/shER $\beta$  or PLKO.1-control/shDAB2IP (kindly provided by Prof. Jer-Tsong Hsieh, UT Southwestern Medical Center at Dallas), to produce lentiviral particles. The supernatants containing lentiviral particles were collected 48 hrs post-transfection of 293T cells, filtered and used to transduce RCC cells for 48 hrs with polybrene. The viral transduced RCC cells were then subjected to 1  $\mu$ g/ml puromycin selection. The detailed procedure was described in our previous published paper [59].

### RNA extraction and quantitative real-time PCR analysis

Total RNA was extracted by Trizol reagent (Invitrogen, CA) according to the manufacturer's instructions. RNAs (1  $\mu$ g) were subjected to reverse transcription using Superscript III transcriptase (Invitrogen). The obtained cDNAs were applied for qPCR using a SYBR green Bio-Rad CFX96 system. The

primers used are in Table 1. RNA expression levels were normalized to the expression of GAPDH.

### Western blot assay

Total protein was extracted by RIPA buffer containing 1% protease inhibitors (Amresco, Cochran, USA). The following primary antibodies were used: rabbit anti-ER $\beta$  polyclonal antibody (GTX 110607, GeneTex), mouse anti-DAB2IP polyclonal antibody (1  $\mu$ g/ml) and mouse anti-GAPDH monoclonal antibody (Santa Cruz), all used at 1:1000 dilution. The immune-positive bands were visualized with an ECL chemiluminescent detection system (Thermo Scientific) and the images were transferred to the Bio-Rad imaging system. All analyses were performed at least in duplicate. The detailed procedure of Western blot was described in our previous publication [60].

### Statistical analysis

Values were expressed as mean  $\pm$  standard deviation (SD). The Student's *t* test and one-way NOVA were

**Table 1: Primer sequences for quantitative PCR**

Gene	Accession No.	sequences
GAPDH	NM_002046	Forward: 5'-GGAGCGAGATCCCTCCAAAAT-3' Reverse: 5'-GGCTGTTGTCATACTTCTCATGG-3'
ER $\beta$	NM_001214902	Forward: 5'-TCCATCGCCAGTTATCACATCT-3' Reverse: 5'-CTGGACCAGTAACAGGGCTG-3'
DAB2IP	NM_138709	Forward: 5'-CTGAGCGGGATAAGTGGATGG-3' Reverse: 5'-AAACATTGTCCGTCTTGAGCTT-3'
HIF-2 $\alpha$	NM_001001392	Forward: 5'-GTGCTCCCACGGCCTGTA-3' Reverse: 5'-TTGTCACACCTATGGCATATCACA-3'
VEGF $\alpha$	NM_001171627	Forward: 5'-AGGGCAGAATCATCACGAAGT-3' Reverse: 5'-AGGGTCTCGATTGGATGGCA-3'
IL-6	NM_000600	Forward: 5'-CCTGAACCTTCCAAAGATGGC-3' Reverse: 5'-TTCACCAGGCAAGTCTCCTCA-3'
IFN- $\gamma$	NM_000619	Forward: 5'-TCGGTAACTGACTTGAATGTCCA-3' Reverse: 5'-TCGCTTCCCTGTTTTAGCTGC-3'
CCL3	NM_002983	Forward: 5'-AGTTCTCTGCATCACTTGCTG-3' Reverse: 5'-CGGCTTCGCTTGGTTAGGAA-3'
CCL4	NM_002984	Forward: 5'-CTGTGCTGATCCCAGTGAATC-3' Reverse: 5'-TCAGTTCAGTTCAGGTCATACA-3'
CCL5	NM_002985	Forward: 5'-CCAGCAGTCGTCTTTGTCAC-3' Reverse: 5'-CTCTGGGTTGGCACACACTT-3'
IGF-1	NM_001111283	Forward: 5'-GCTCTTCAGTTCGTGTGTGGA-3' Reverse: 5'-GCCTCCTTAGATCACAGCTCC-3'
FGF-7	NM_002009	Forward: 5'-TCCTGCCAACTTTGCTCTACA-3' Reverse: 5'-CAGGGCTGGAACAGTTCACAT-3'

used to calculate two-sided *P* values, and considered statistically significant when *P* < 0.05.

## ACKNOWLEDGMENTS

We thank Dr. Chawnshang Chang and Karen Wolf for help with manuscript preparation. PLKO.1-control/shDAB2IP was kindly provided by Prof. Jer-Tsong Hsieh, UT Southwestern Medical Center at Dallas.

## CONFLICTS OF INTEREST

The authors confirm that there are no conflicts of interest.

## REFERENCES

1. Kumar V, Abbas AK, Fausto N, Aster JC. Robbins and Cotran Pathologic Basis of Disease, Professional Edition: Expert Consult-Online: Elsevier Health Sciences. 2009.
2. Srigley JR, Delahunt B, Eble JN, Egevad L, Epstein JI, Grignon D, Hes O, Moch H, Montironi R, Tickoo SK, Zhou M, Argani P, Panel IRT. The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. *Am J Surg Pathol.* 2013; 37:1469–1489.
3. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. *Lancet.* 2009; 373:1119–1132.
4. Vogelzang NJ, Stadler WM. Kidney cancer. *The Lancet.* 1998; 352:1691–1696.
5. Bizzarri M, Cucina A. Tumor and the microenvironment: a chance to reframe the paradigm of carcinogenesis? *BioMed research international.* 2014; 2014:934038.
6. Noessner E, Brech D, Mendler AN, Masouris I, Schlenker R, Prinz PU. Intratumoral alterations of dendritic-cell differentiation and CD8(+) T-cell anergy are immune escape mechanisms of clear cell renal cell carcinoma. *Oncoimmunology.* 2012; 1:1451–1453.
7. Minárik I, Lašťovička J, Budinský V, Kayserová J, Špišek R, Jarolím L, Fialová A, Babjuk M, Bartůňková J. Regulatory T cells, dendritic cells and neutrophils in

- patients with renal cell carcinoma. *Immunology letters*. 2013; 152:144–150.
8. Van den Hove L, Van Gool S, Van Poppel H, Baert L, Coorevits L, Van Damme B, Ceuppens J. Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma. *Clinical & Experimental Immunology*. 1997; 109:501–509.
  9. Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horak I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. *Cell*. 1993; 75:253–261.
  10. Sadlack B, Lohler J, Schorle H, Klebb G, Haber H, Sickel E, Noelle RJ, Horak I. Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4<sup>+</sup> T cells. *Eur J Immunol*. 1995; 25:3053–3059.
  11. Attig S, Hennenlotter J, Pawelec G, Klein G, Koch SD, Pircher H, Feyerabend S, Wernet D, Stenzl A, Rammensee H-G. Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas. *Cancer research*. 2009; 69:8412–8419.
  12. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. *Nat Med*. 2004; 10:942–949.
  13. Sommer S, Fuqua SA. Estrogen receptor and breast cancer. *Seminars in cancer biology*: Elsevier. 2001; 339–352.
  14. Knight WA, Livingston RB, Gregory EJ, McGuire WL. Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. *Cancer research*. 1977; 37:4669–4671.
  15. Chen M, Yeh CR, Chang HC, Vitkus S, Wen XQ, Bhowmick NA, Wolfe A, Yeh S. Loss of epithelial oestrogen receptor alpha inhibits oestrogen-stimulated prostate proliferation and squamous metaplasia via *in vivo* tissue selective knockout models. *J Pathol*. 2012; 226:17–27.
  16. Hsu I, Yeh CR, Slavin S, Miyamoto H, Netto GJ, Tsai YC, Muyan M, Wu XR, Messing EM, Guancial EA, Yeh S. Estrogen receptor alpha prevents bladder cancer via INPP4B inhibited akt pathway *in vitro* and *in vivo*. *Oncotarget*. 2014; 5:7917–7935.
  17. Hsu I, Chuang KL, Slavin S, Da J, Lim WX, Pang ST, O'Brien JH, Yeh S. Suppression of ERbeta signaling via ERbeta knockout or antagonist protects against bladder cancer development. *Carcinogenesis*. 2014; 35:651–661.
  18. Hsu I, Vitkus S, Da J, Yeh S. Role of oestrogen receptors in bladder cancer development. *Nat Rev Urol*. 2013; 10:317–326.
  19. Yeh CR, Hsu I, Song W, Chang H, Miyamoto H, Xiao GQ, Li L, Yeh S. Fibroblast ERalpha promotes bladder cancer invasion via increasing the CCL1 and IL-6 signals in the tumor microenvironment. *Am J Cancer Res*. 2015; 5:1146–1157.
  20. Song W, Yeh CR, He D, Wang Y, Xie H, Pang ST, Chang LS, Li L, Yeh S. Infiltrating neutrophils promote renal cell carcinoma progression via VEGFa/HIF2alpha and estrogen receptor beta signals. *Oncotarget*. 2015; 6:10290–10304.
  21. Sato K, Tsuchiya N, Sasaki R, Shimoda N, Satoh S, Ogawa O, Kato T. Increased serum levels of vascular endothelial growth factor in patients with renal cell carcinoma. *Cancer Science*. 1999; 90:874–879.
  22. Morris MR, Hughes DJ, Tian Y-M, Ricketts CJ, Lau KW, Gentle D, Shuib S, Serrano-Fernandez P, Lubinski J, Wiesener MS. Mutation analysis of hypoxia-inducible factors HIF1A and HIF2A in renal cell carcinoma. *Anticancer research*. 2009; 29:4337–4343.
  23. Chen H, Toyooka S, Gazdar AF, Hsieh J-T. Epigenetic regulation of a novel tumor suppressor gene (hDAB2IP) in prostate cancer cell lines. *Journal of Biological Chemistry*. 2003; 278:3121–3130.
  24. Duggan D, Zheng SL, Knowlton M, Benitez D, Dimitrov L, Wiklund F, Robbins C, Isaacs SD, Cheng Y, Li G. Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. *Journal of the National Cancer Institute*. 2007; 99:1836–1844.
  25. Wu K, Liu J, Tseng S, Gore C, Ning Z, Sharifi N, Fazli L, Gleave M, Kapur P, Xiao G. The role of DAB2IP in androgen receptor activation during prostate cancer progression. *Oncogene*. 2014; 33:1954–1963.
  26. Stanford MM, Issekutz TB. The relative activity of CXCR3 and CCR5 ligands in T lymphocyte migration: concordant and disparate activities *in vitro* and *in vivo*. *J Leukoc Biol*. 2003; 74:791–799.
  27. Lee A, Weng C, Jackson J, Yee D. Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells. *Journal of Endocrinology*. 1997; 152:39–47.
  28. Lam JS, Shvarts O, Leppert JT, Figlin RA, Belldegrun AS. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. *The Journal of urology*. 2005; 173:1853–1862.
  29. Bremnes RM, Al-Shibli K, Donnem T, Sirera R, Al-Saad S, Andersen S, Stenvold H, Camps C, Busund LT. The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer. *J Thorac Oncol*. 2011; 6:824–833.
  30. Man YG, Stojadinovic A, Mason J, Avital I, Bilchik A, Bruecher B, Protic M, Nissan A, Izadjoo M, Zhang X, Jewett A. Tumor-infiltrating immune cells promoting tumor invasion and metastasis: existing theories. *J Cancer*. 2013; 4:84–95.
  31. Whiteside TL. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. *Semin Cancer Biol*. 2006; 16:3–15.

32. Sakaguchi S, Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T. Regulatory T cells: how do they suppress immune responses? *Int Immunol*. 2009; 21:1105–1111.
33. Sakaguchi S. Naturally arising Foxp3-expressing CD25+ CD4+ regulatory T cells in immunological tolerance to self and non-self. *Nature immunology*. 2005; 6:345–352.
34. Serel TA, Soyupek S, Candir O. Association between mast cells and bladder carcinoma. *Urol Int*. 2004; 72:299–302.
35. Pages F, Galon J, Dieu-Nosjean MC, Tartour E, Sautes-Fridman C, Fridman WH. Immune infiltration in human tumors: a prognostic factor that should not be ignored. *Oncogene*. 2010; 29:1093–1102.
36. Polimeno M, Napolitano M, Costantini S, Portella L, Esposito A, Capone F, Guerriero E, Trotta A, Zanotta S, Pucci L, Longo N, Perdoni S, Pignata S, et al. Regulatory T cells, interleukin (IL)-6, IL-8, vascular endothelial growth factor (VEGF), CXCL10, CXCL11, epidermal growth factor (EGF) and hepatocyte growth factor (HGF) as surrogate markers of host immunity in patients with renal cell carcinoma. *BJU Int*. 2013; 112:686–696.
37. Horwitz DA, Zheng SG, Gray JD. Natural and TGF- $\beta$ -induced Foxp3+ CD4+ CD25+ regulatory T cells are not mirror images of each other. *Trends in immunology*. 2008; 29:429–435.
38. Fulop V, Colitti CV, Genest D, Berkowitz RS, Yiu GK, Ng SW, Szepesi J, Mok SC. DOC-2/hDab2, a candidate tumor suppressor gene involved in the development of gestational trophoblastic diseases. *Oncogene*. 1998; 17:419–424.
39. Wang Z, Tseng CP, Pong RC, Chen H, McConnell JD, Navone N, Hsieh JT. The mechanism of growth-inhibitory effect of DOC-2/DAB2 in prostate cancer. Characterization of a novel GTPase-activating protein associated with N-terminal domain of DOC-2/DAB2. *J Biol Chem*. 2002; 277:12622–12631.
40. Xie D, Gore C, Zhou J, Pong R-C, Zhang H, Yu L, Vessella RL, Min W, Hsieh J-T. DAB2IP coordinates both PI3K-Akt and ASK1 pathways for cell survival and apoptosis. *Proceedings of the National Academy of Sciences*. 2009; 106:19878–19883.
41. Shen YJ, Kong ZL, Wan FN, Wang HK, Bian XJ, Gan HL, Wang CF, Ye DW. Downregulation of DAB2IP results in cell proliferation and invasion and contributes to unfavorable outcomes in bladder cancer. *Cancer Sci*. 2014; 105:704–712.
42. Zhou J, Wu K, Kapur P, Pong R-C, Zhu G, He D, Hsieh J-T. 300 Correlation of loss of dab2ip gene expression with different subtypes of renal cell carcinoma and its mechanism of action. *The Journal of Urology*. 2013; 189:e122.
43. Chen H, Tu S-w, Hsieh J-T. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer. *Journal of Biological Chemistry*. 2005; 280:22437–22444.
44. Greathouse KL, Bredfeldt T, Everitt JI, Lin K, Berry T, Kannan K, Mittelstadt ML, Ho S-m, Walker CL. Environmental estrogens differentially engage the histone methyltransferase EZH2 to increase risk of uterine tumorigenesis. *Molecular Cancer Research*. 2012; 10:546–557.
45. Peng W, Liu C, Xu C, Lou Y, Chen J, Yang Y, Yagita H, Overwijk WW, Lizee G, Radvanyi L, Hwu P. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-gamma inducible chemokines. *Cancer Res*. 2012; 72:5209–5218.
46. Wen X, Kudo T, Payne L, Wang X, Rodgers L, Suzuki Y. Predominant interferon-gamma-mediated expression of CXCL9, CXCL10, and CCL5 proteins in the brain during chronic infection with *Toxoplasma gondii* in BALB/c mice resistant to development of toxoplasmic encephalitis. *J Interferon Cytokine Res*. 2010; 30:653–660.
47. Panzer U, Reinking RR, Steinmetz OM, Zahner G, Sudbeck U, Fehr S, Pfalzer B, Schneider A, Thaiss F, Mack M. CXCR3 and CCR5 positive T-cell recruitment in acute human renal allograft rejection. *Transplantation*. 2004; 78:1341–1350.
48. Groom JR, Luster AD. CXCR3 in T cell function. *Experimental cell research*. 2011; 317:620–631.
49. Hariharan D, Douglas SD, Lee B, Lai JP, Campbell DE, Ho WZ. Interferon-gamma upregulates CCR5 expression in cord and adult blood mononuclear phagocytes. *Blood*. 1999; 93:1137–1144.
50. Loetscher P, Uguccioni M, Bordoli L, Baggiolini M, Moser B, Chizzolini C, Dayer JM. CCR5 is characteristic of Th1 lymphocytes. *Nature*. 1998; 391:344–345.
51. Ajuebor MN, Hogaboam CM, Le T, Proudfoot AE, Swain MG. CCL3/MIP-1 $\alpha$  is pro-inflammatory in murine T cell-mediated hepatitis by recruiting CCR1-expressing CD4+ T cells to the liver. *European journal of immunology*. 2004; 34:2907–2918.
52. Gaga M, Ong YE, Benyahia F, Aizen M, Barkans J, Kay A. Skin reactivity and local cell recruitment in human atopic and nonatopic subjects by CCL2/MCP-1 and CCL3/MIP-1 $\alpha$ . *Allergy*. 2008; 63:703–711.
53. Barczyk A, Pierzchała E, Caramori G, Sozanska E. Increased expression of CCL4/MIP-1 $\beta$  in CD8+ cells and CD4+ cells in sarcoidosis. *Int J Immunopathol Pharmacol*. 2014; 27:185–193.
54. Cheng NL, Chen X, Kim J, Shi AH, Nguyen C, Wersto R, Weng NP. MicroRNA-125b modulates inflammatory chemokine CCL4 expression in immune cells and its reduction causes CCL4 increase with age. *Aging Cell*. 2015; 14:200–208.
55. Khuu CH, Barrozo RM, Hai T, Weinstein SL. Activating transcription factor 3 (ATF3) represses the expression of CCL4 in murine macrophages. *Mol Immunol*. 2007; 44:1598–1605.
56. Richardson AE, Hamilton N, Davis W, Brito C, De Leon D. Insulin-like growth factor-2 (IGF-2) activates estrogen

- receptor-alpha and -beta via the IGF-1 and the insulin receptors in breast cancer cells. *Growth Factors*. 2011; 29:82–93.
57. Nagasawa K, Mak TW. Phorbol esters induce differentiation in human malignant T lymphoblasts. *Proceedings of the National Academy of Sciences*. 1980; 77: 2964–2968.
58. Tarella C, Ferrero D, Gallo E, Pagliardi GL, Ruscetti FW. Induction of differentiation of HL-60 cells by dimethyl sulfoxide: evidence for a stochastic model not linked to the cell division cycle. *Cancer Res*. 1982; 42:445–449.
59. Raval RR, Lau KW, Tran MG, Sowter HM, Mandriota SJ, Li J-L, Pugh CW, Maxwell PH, Harris AL, Ratcliffe PJ. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. *Molecular and cellular biology*. 2005; 25:5675–5686.
60. Slavin S, Yeh CR, Da J, Yu S, Miyamoto H, Messing EM, Guancial E, Yeh S. Estrogen receptor alpha in cancer-associated fibroblasts suppresses prostate cancer invasion via modulation of thrombospondin 2 and matrix metalloproteinase 3. *Carcinogenesis*. 2014; 35:1301–1309.